BAMS
Bellevue Asset Management (Switzerland) Portfolio holdings
AUM
$656M
This Quarter Return
+10.91%
1 Year Return
+11.48%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$656M
AUM Growth
+$656M
(+7%)
Cap. Flow
-$2.4M
Cap. Flow
% of AUM
-0.37%
Top 10 Holdings %
Top 10 Hldgs %
31%
Holding
140
New
7
Increased
41
Reduced
25
Closed
13
Top Buys
| 1 |
Cardinal Health
CAH
|
$8.17M |
| 2 |
Centene
CNC
|
$5.64M |
| 3 |
Viatris
VTRS
|
$4.88M |
| 4 |
Eagle Bancorp
EGBN
|
$4.88M |
| 5 |
LCI
Lannett Company, Inc.
LCI
|
$4.31M |
Top Sells
| 1 |
AGN
Allergan plc
AGN
|
$13.6M |
| 2 |
Dr. Reddy's Laboratories
RDY
|
$8.31M |
| 3 |
KITE
Kite Pharma, Inc.
KITE
|
$6.5M |
| 4 |
Abbott
ABT
|
$3.66M |
| 5 |
Tenet Healthcare
THC
|
$3.53M |
Sector Composition
| 1 | Healthcare | 93.1% |
| 2 | Financials | 1.62% |
| 3 | Industrials | 0.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ACHN
51
DELISTED
Achillion Pharmaceuticals, Inc.
ACHN
| $4.53M | 0.69% |
420,000
| – | – |
|
|
LCI
52
DELISTED
Lannett Company, Inc.
LCI
| $4.31M | 0.66% |
+107,480
| New | +$4.31M |
|
53
Baxter International
BAX
$12.7B
| $4.2M | 0.64% |
110,000
+60,000
| +120% | +$2.29M |
|
54
Elevance Health
ELV
$71.8B
| $4.18M | 0.64% |
30,000
| – | – |
|
55
Bristol-Myers Squibb
BMY
$96B
| $4.13M | 0.63% |
60,000
| – | – |
|
56
HCA Healthcare
HCA
$94.5B
| $4.06M | 0.62% |
60,000
+20,000
| +50% | +$1.35M |
|
57
Neurocrine Biosciences
NBIX
$13.8B
| $3.68M | 0.56% |
65,000
| – | – |
|
58
Nektar Therapeutics
NKTR
$568M
| $3.64M | 0.55% |
216,000
-24,000
| -10% | -$404K |
|
|
CERN
59
DELISTED
Cerner Corp
CERN
| $3.61M | 0.55% |
60,000
+5,000
| +9% | +$301K |
|
60
Pfizer
PFE
$141B
| $3.55M | 0.54% |
110,000
+25,000
| +29% | +$807K |
|
61
Agios Pharmaceuticals
AGIO
$2.19B
| $3.51M | 0.53% |
54,000
| – | – |
|
|
NVDQ
62
DELISTED
Novadaq Technologies Inc.
NVDQ
| $3.19M | 0.49% |
250,000
| – | – |
|
63
Merck
MRK
$210B
| $3.17M | 0.48% |
60,000
| – | – |
|
64
Hologic
HOLX
$14.9B
| $3.13M | 0.48% |
81,000
| – | – |
|
65
Masimo
MASI
$7.59B
| $3.11M | 0.47% |
75,000
| – | – |
|
|
ARIA
66
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $3.09M | 0.47% |
495,000
| – | – |
|
|
SGEN
67
DELISTED
Seagen Inc. Common Stock
SGEN
| $3.05M | 0.47% |
68,000
+20,000
| +42% | +$898K |
|
|
MDVN
68
DELISTED
MEDIVATION, INC.
MDVN
| $3.05M | 0.46% |
63,000
+10,400
| +20% | +$503K |
|
|
VAR
69
DELISTED
Varian Medical Systems, Inc.
VAR
| $2.99M | 0.46% |
37,000
| – | – |
|
70
Eli Lilly
LLY
$657B
| $2.95M | 0.45% |
35,000
| – | – |
|
71
Thermo Fisher Scientific
TMO
$186B
| $2.84M | 0.43% |
20,000
| – | – |
|
72
Novavax
NVAX
$1.21B
| $2.73M | 0.42% |
325,000
| – | – |
|
73
MacroGenics
MGNX
$112M
| $2.57M | 0.39% |
83,000
| – | – |
|
|
QGENF
74
DELISTED
QIAGEN NV
QGENF
| $2.53M | 0.39% |
91,500
+11,500
| +14% | +$318K |
|
75
Celldex Therapeutics
CLDX
$1.47B
| $2.51M | 0.38% |
160,000
| – | – |
|